论文部分内容阅读
目的 :评价HP联合化疗方案治疗晚期难治性转移性乳腺癌的安全性 ,可行性及有效性。方法 :对 30例有可测量的病变 ,卡氏评分≥ 70分 ,曾经应用CMF、CAF方案治疗无效的乳腺癌患者行HP方案化疗。HCPT 8mg/m2 ivgttd1～ 5 ,DDP 15mg/m2 ivgttd1～ 5 ,2 1天为一周期。至少治疗 2个周期以上。结果 :全组 30例 ,CR 4例 ,PR 12例 ,总有效率 5 3 3%。毒副反应主要是白细胞及血小板下降 ,发生率分别为 80 %和 30 % ,白细胞Ⅲ、Ⅳ度毒性为 10 %和 6 7%。未见心肝肾重要脏器损害。结论 :HP方案治疗晚期难治性乳腺癌较为满意且安全可行。
Objective: To evaluate the safety, feasibility and effectiveness of HP combined chemotherapy in the treatment of advanced refractory metastatic breast cancer. Methods: 30 cases of measurable lesions, Karnofsky score ≥ 70 points, once the application of CMF, CAF regimen ineffective treatment of breast cancer patients with HP regimen chemotherapy. HCPT 8mg / m2 ivgttd1 ~ 5, DDP 15mg / m2 ivgttd1 ~ 5, 2 1 days for a cycle. At least 2 cycles or more. Results: The whole group of 30 patients, CR 4 cases, PR 12 cases, the total efficiency of 533%. Toxic and side effects mainly white blood cells and thrombocytopenia, the incidence rates were 80% and 30%, white blood cells Ⅲ, Ⅳ degree of toxicity was 10% and 67%. No significant heart and liver and kidney damage. Conclusion: HP regimen is more satisfactory and safe for the treatment of advanced refractory breast cancer.